The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 34, Issue 2, 2016, Pages 318-328

  Hodge, Jennifer A ^a   Kawabata, Thomas T ^a   Krishnaswami, Sriram ^a   Clark, James D ^a   Telliez, Jean Baptiste ^a   Dowty, Martin E ^a   Menon, Sujatha ^a   Lamba, Manisha ^a   Zwillich, Samuel ^a  

^a PFIZER INC   (United States)

Author keywords

Cytokines; Immune response; Janus kinase; Rheumatoid arthritis; Tofacitinib

Indexed keywords

CYTOKINE; JANUS KINASE; STAT PROTEIN; TOFACITINIB; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MOLECULARLY TARGETED THERAPY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; VACCINATION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG EFFECTS; IMMUNOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; JANUS KINASES; LYMPHOCYTE SUBSETS; NEUTROPHILS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION;

EID: 84963905058     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. LEE DM, WEINBLATT ME: Rheumatoid arthritis. Lancet 2001; 358: 903-11
2. McINNES IB, SCHETT G: Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-42
3. OTERO M, GOLDRING MB: Cells of the synovium in rheumatoid arthritis. Chondrocytes. Arthritis Res Ther 2007; 9: 220
4. SCHETT G, STACH C, ZWERINA J, VOLL R, MANGER B: How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2936-48
5. McINNES IB, LIEW FY: Cytokine networks-towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2005; 1: 31-9
6. O'SHEA JJ: Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis 2004; 63 (Suppl. 2): ii67-ii71
7. MAVERS M, RUDERMAN EM, PERLMAN H: Intracellular signal pathways: potential for therapies. Curr Rheumatol Rep 2009; 11: 378-85
8. O'SULLIVAN LA, LIONGUE C, LEWIS RS, STEPHENSON SEM, WARD AC: Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol 2007; 44: 2497-506
9. LUBBERTS E: Th17 cytokines and arthritis. Semin Immunopathol 2010; 32: 43-53
10. GHORESCHI K, LAURENCE A, O'SHEA JJ: Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-87
11. PESU M, LAURENCE A, KISHORE N et al.: Therapeutic targeting of Janus kinases. Immunol Rev 2008; 223: 132-42
12. SHUAI K, LIU B: Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003; 3: 900-11
13. O'SHEA JJ, MURRAY PJ: Cytokine signaling modules in inflammatory responses. Immunity 2008; 28: 477-87
14. FIRESTEIN GS: Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61
15. MEYER DM, JESSON MI, LI X et al.: Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690, 550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7: 41
16. GHORESCHI K, JESSON MI, LI X et al.: Modulation of innate and adaptive immune responses by tofacitinib (CP-690, 550). J Immunol 2011; 186: 4234-43
17. DOWTY ME, JESSON MI, GHOSH S et al.: Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. J Pharmacol Exp Ther 2014; 348: 165-73
18. LABRANCHE TP, JESSON MI, RADI ZA et al.: JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 2012; 64: 3531-42
19. van der HEIJDE D, TANAKA Y, FLEISCHMANN R et al.: Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65: 559-70
20. van VOLLENHOVEN RF, FLEISCHMANN R, COHEN S et al.: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-19
21. FLEISCHMANN R, KREMER J, CUSH J et al.: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507
22. KREMER J, LI ZG, HALL S et al.: Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013; 159: 253-61
23. BURMESTER GR, BLANCO R, CHARLES-SCHOEMAN C et al.: Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-60
24. LEE EB, FLEISCHMANN R, HALL S et al.: Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370: 2377-86
25. PFIZER INC.: Xeljanz prescribing information. Available at http://labeling.pfizer.com/ShowLabeling.aspx?id=959. Last updated May 2014. Accessed 22 July 2014
26. KREMER JM, BLOOM BJ, BREEDVELD FC et al.: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebocontrolled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum 2009; 60: 1895-905
27. KREMER JM, COHEN S, WILKINSON BE et al.: A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012; 64: 970-81
28. TANAKA Y, SUZUKI M, NAKAMURA H, TOYOIZUMI S, ZWILLICH SH: Phase II study of tofacitinib (CP-690, 550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011; 63: 1150-8
29. TANAKA Y, TAKEUCHI T, YAMANAKA H et al.: Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, Phase 2 study. Mod Rheumatol 2015; 25: 514-21
30. FLEISCHMANN R, CUTOLO M, GENOVESE MC et al.: Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64: 617-29
31. GENOVESE MC, KAWABATA T, SOMA K et al.: Reversibility of pharmacodynamic effects after short-and long-term treatment with tofacitinib in patients with rheumatoid arthritis. Arthritis Rheum 2013; 65: S193
32. STROBER B, BUONANNO M, CLARK JD et al.: Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 2013; 169: 992-9
33. van GURP EA, SCHOORDIJK-VERSCHOOR W, KLEPPER M et al.: The effect of the JAK inhibitor CP-690, 550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 2009; 87: 79-86
34. ROBERTS JL, LENGI A, BROWN SM et al.: Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood 2004; 103: 2009-18
35. FURST DE: Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 2009; 39: 18-29
36. GONZALEZ-QUINTELA A, ALENDE R, GUDE F et al.: Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol 2008; 151: 42-50
37. STIEHM ER, FUDENBERG HH: Serum levels of immune globulins in health and disease: a survey. Pediatrics 1966; 37: 715-27
38. BARDEN J, MULLINAX F, WALLER M: Immunoglobulin levels in rhuematoid arthritis: comparison with rhuematoid factor titers, clinical stage and disease duration. Arthritis Rheum 1967; 10: 228-34
39. JORGENSEN C, ANAYA JM, COGNOT C, SANY J: Rheumatoid arthritis associated with high levels of immunoglobulin a: clinical and biological characteristics. Clin Exp Rheumatol 1992; 10: 571-5
40. VEYS EM, CLAESSENS HE: Serum levels of IgG, IgM, and IgA in rheumatoid arthritis. Ann Rheum Dis 1968; 27: 431-40
41. JENTSCH-ULLRICH K, KOENIGSMANN M, MOHREN M, FRANKE A: Lymphocyte subsets' reference ranges in an age-and genderbalanced population of 100 healthy adults-a monocentric German study. Clin Immunol 2005; 116: 192-7
42. BISSET LR, LUNG TL, KAELIN M, LUDWIG E, DUBS RW: Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol 2004; 72: 203-12
43. WINTHROP KL, SILVERFIELD J, RACEWICZ A et al.: The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 2015 Mar 20 [Epub ahead of print]
44. WINTHROP KL, RACEWICZ A, LEE EB et al.: Evaluation of influenza and pneumococcal vaccine responses in rheumatoid arthritis patients using tofacitinib. Arthritis Rheum 2012; 64: S550
45. WINTHROP KL, NEAL J, HRYCAJ P et al.: Evaluation of Influenza and Pneumococcal Vaccine Responses in Rheumatoid Arthritis Patients using tofacitinib. Ann Rheum Dis 2013; 72: 107
46. MAESHIMA K, YAMAOKA K, KUBO S et al.: The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 2012; 64: 1790-8
47. MIGITA K, MIYASHITA T, IZUMI Y et al.: Inhibitory effects of the JAK inhibitor CP690, 550 on human CD4(+) T lymphocyte cytokine production. BMC Immunol 2011; 12: 51
48. MIGITA K, KOGA T, KOMORI A et al.: Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. J Rheumatol 2011; 38: 2309-17
49. ROSENGREN S, CORR M, FIRESTEIN GS, BOYLE DL: The JAK inhibitor CP-690, 550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012; 71: 440-7
50. YARILINA A, XU K, CHAN C, IVASHKIV LB: Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum 2012; 64: 3856-66
51. DOWTY ME, LIN J, RYDER TF et al.: The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos 2014; 42: 759-73